LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Akcijų sąrašas・InflaRx NV

InflaRx NV

Uždarymo kaina

2 -3.38

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.97

Max

2.07

Pagrindiniai rodikliai
By Trading Economics
Pajamos	3.2M -5.7M
Pelnas, tenkantis vienai akcijai	-0.08
Pelno marža	16,200.567
Darbuotojai	65
EBITDA	8.5M -5.5M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+288.35% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	166M 320M
Ankstesnė atidarymo kaina	5.38
Ankstesnė uždarymo kaina	2

InflaRx NV Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-04 21:51; UTC

Pagrindinės rinkos jėgos

Merlin Shares Rally After Defense Department's Design Review Wraps

2026-06-04 23:46; UTC

Rinkos pokalbiai

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

2026-06-04 23:44; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-06-04 23:42; UTC

Įsigijimai, susijungimai, perėmimai

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

2026-06-04 23:41; UTC

Įsigijimai, susijungimai, perėmimai

Energy Resources of Australia to Enter Trading Halt

2026-06-04 23:34; UTC

Rinkos pokalbiai

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-04 23:08; UTC

Rinkos pokalbiai

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

2026-06-04 22:41; UTC

Rinkos pokalbiai

Australia Shares Set to Rise at the Open -- Market Talk

2026-06-04 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-04 20:44; UTC

Įsigijimai, susijungimai, perėmimai

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

2026-06-04 20:16; UTC

Rinkos pokalbiai

Mexican Demand Indicators Show Signs of Life -- Market Talk

2026-06-04 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

2026-06-04 19:46; UTC

Rinkos pokalbiai

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

2026-06-04 19:38; UTC

Rinkos pokalbiai

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

2026-06-04 19:30; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

2026-06-04 18:47; UTC

Įsigijimai, susijungimai, perėmimai

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

2026-06-04 18:38; UTC

Uždarbis

Money Quote: Tech Weakness in Context -- WSJ

2026-06-04 18:24; UTC

Uždarbis

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-04 17:09; UTC

Rinkos pokalbiai

Retest of $55k Seen Possible for Bitcoin -- Market Talk

2026-06-04 16:58; UTC

Uždarbis

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-04 16:46; UTC

Rinkos pokalbiai

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

2026-06-04 16:38; UTC

Uždarbis

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

2026-06-04 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-04 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-06-04 16:13; UTC

Rinkos pokalbiai

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

2026-06-04 16:11; UTC

Rinkos pokalbiai

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

2026-06-04 15:56; UTC

Rinkos pokalbiai

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Akcijų palyginimas

Kainos pokytis

InflaRx NV Prognozė

Kainos tikslas

By TipRanks

288.35% į viršų

12 mėnesių prognozė

Vidutinis 8 USD 288.35%

Aukščiausias 14 USD

Žemiausias 4 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines InflaRx NV kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių InflaRx NV akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę InflaRx NV

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.